Balaji Prasad
Stock Analyst at Barclays
(3.48)
# 923
Out of 5,055 analysts
132
Total ratings
48.39%
Success rate
4.7%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $6.95 | +259.71% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $11.58 | -5.01% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $23.88 | +0.50% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $10.66 | -15.57% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $170.09 | +17.58% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $21.42 | -11.30% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $74.17 | -19.10% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $118.80 | +105.39% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $7.65 | +213.73% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $45.01 | -51.12% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $669.00 | -22.27% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $24.59 | +5.73% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.96 | +21.78% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $5.14 | +250.19% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.64 | +175.10% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.13 | +519.47% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $6.95
Upside: +259.71%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $11.58
Upside: -5.01%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $23.88
Upside: +0.50%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $10.66
Upside: -15.57%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $170.09
Upside: +17.58%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $21.42
Upside: -11.30%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $74.17
Upside: -19.10%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $118.80
Upside: +105.39%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $7.65
Upside: +213.73%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $45.01
Upside: -51.12%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $669.00
Upside: -22.27%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $24.59
Upside: +5.73%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.96
Upside: +21.78%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $5.14
Upside: +250.19%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.64
Upside: +175.10%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.13
Upside: +519.47%